合計 50 件の最近のインサイダー取引記録が記録されています Enanta Pharmaceuticals, Inc. (ENTA), 内訳は 27 件の買い および 21 件の売り. インサイダー買い総額は $13.93M インサイダー売り総額は $378.04K.
最近活動のある主要インサイダーには Carter Bruce L A, Foletta Mark G, Russell Lesley. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — ENTA
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-11 |
Carter Bruce L A |
Director |
RSU 付与（制限付株式） |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Foletta Mark G |
Director |
RSU 付与（制限付株式） |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Russell Lesley |
Director |
RSU 付与（制限付株式） |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Peterson Kristine |
Director |
RSU 付与（制限付株式） |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Vance Terry |
Director |
RSU 付与（制限付株式） |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-03-11 |
Hata Yujiro S |
Director |
RSU 付与（制限付株式） |
20,000 |
$14.17 |
$283.4K |
20,000 |
| 2026-02-12 |
Luly Jay R. |
President and CEO |
RSU 付与（制限付株式） |
4,800 |
- |
- |
862,826 |
| 2026-02-12 |
Or Yat Sun |
Chief Scientific Officer |
RSU 付与（制限付株式） |
1,650 |
- |
- |
373,042 |
| 2026-02-12 |
Kowalsky Matthew Paul |
Chief Legal Officer |
RSU 付与（制限付株式） |
1,318 |
- |
- |
1,318 |
| 2026-02-12 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
RSU 付与（制限付株式） |
1,575 |
- |
- |
32,195 |
| 2026-02-12 |
Luu Brendan |
Chief Business Officer |
RSU 付与（制限付株式） |
1,575 |
- |
- |
39,904 |
| 2026-02-12 |
Rottinghaus Scott T. |
Chief Medical Officer |
RSU 付与（制限付株式） |
1,650 |
- |
- |
23,442 |
| 2025-12-05 |
Luly Jay R. |
President and CEO |
情報に基づく売り |
4,743 |
$14.23 |
$67.49K |
858,026 |
| 2025-12-05 |
Or Yat Sun |
Chief Scientific Officer |
情報に基づく売り |
2,390 |
$14.23 |
$34.01K |
371,392 |
| 2025-12-05 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
情報に基づく売り |
2,106 |
$14.23 |
$29.97K |
30,620 |
| 2025-12-05 |
Luu Brendan |
Chief Business Officer |
情報に基づく売り |
1,394 |
$14.23 |
$19.84K |
38,329 |
| 2025-12-05 |
Rottinghaus Scott T. |
Chief Medical Officer |
情報に基づく売り |
798 |
$14.23 |
$11.36K |
21,792 |
| 2025-12-05 |
Trout Harry R. Iii |
See Remarks |
情報に基づく売り |
542 |
$14.23 |
$7.71K |
16,348 |
| 2025-12-05 |
Capps Kathleen S. |
See Remarks |
情報に基づく売り |
323 |
$14.23 |
$4.6K |
8,377 |
| 2025-12-02 |
Trout Harry R. Iii |
See Remarks |
情報に基づく売り |
380 |
$13.96 |
$5.3K |
16,890 |
| 2025-12-02 |
Capps Kathleen S. |
See Remarks |
情報に基づく売り |
207 |
$13.96 |
$2.89K |
8,700 |
| 2025-12-01 |
Luly Jay R. |
President and CEO |
RSU 源泉徴収 |
1,885 |
$14.12 |
$26.62K |
862,769 |
| 2025-12-01 |
Or Yat Sun |
Chief Scientific Officer |
RSU 源泉徴収 |
753 |
$14.12 |
$10.63K |
373,782 |
| 2025-12-01 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
RSU 源泉徴収 |
753 |
$14.12 |
$10.63K |
32,726 |
| 2025-12-01 |
Luu Brendan |
Chief Business Officer |
RSU 源泉徴収 |
498 |
$14.12 |
$7.03K |
39,723 |
| 2025-12-01 |
Trout Harry R. Iii |
See Remarks |
RSU 源泉徴収 |
105 |
$14.12 |
$1.48K |
17,270 |
| 2025-12-01 |
Capps Kathleen S. |
See Remarks |
RSU 源泉徴収 |
85 |
$14.12 |
$1.2K |
8,907 |
| 2025-11-25 |
Luly Jay R. |
President and CEO |
RSU 付与（制限付株式） |
310,000 |
$13.66 |
$4.23M |
310,000 |
| 2025-11-25 |
Or Yat Sun |
Chief Scientific Officer |
RSU 付与（制限付株式） |
110,000 |
$13.66 |
$1.5M |
110,000 |
| 2025-11-25 |
Kowalsky Matthew Paul |
Chief Legal Officer |
RSU 付与（制限付株式） |
90,000 |
$13.66 |
$1.23M |
90,000 |
| 2025-11-25 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
RSU 付与（制限付株式） |
100,000 |
$13.66 |
$1.37M |
100,000 |
| 2025-11-25 |
Luu Brendan |
Chief Business Officer |
RSU 付与（制限付株式） |
90,000 |
$13.66 |
$1.23M |
90,000 |
| 2025-11-25 |
Rottinghaus Scott T. |
Chief Medical Officer |
RSU 付与（制限付株式） |
110,000 |
$13.66 |
$1.5M |
110,000 |
| 2025-11-25 |
Trout Harry R. Iii |
See Remarks |
RSU 付与（制限付株式） |
12,925 |
$13.66 |
$176.56K |
12,925 |
| 2025-11-25 |
Capps Kathleen S. |
See Remarks |
RSU 付与（制限付株式） |
6,325 |
$13.66 |
$86.4K |
6,325 |
| 2025-08-26 |
Trout Harry R. Iii |
Vice President, Finance |
不明 |
10,000 |
$63.35 |
$633.5K |
- |
| 2025-08-26 |
Capps Kathleen S. |
See Remarks |
不明 |
8,125 |
$63.35 |
$514.72K |
- |
| 2025-08-08 |
Rottinghaus Scott T. |
Chief Medical Officer |
RSU 源泉徴収 |
2,217 |
$6.99 |
$15.5K |
22,590 |
| 2025-03-13 |
Carter Bruce L A |
Director |
RSU 付与（制限付株式） |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Foletta Mark G |
Director |
RSU 付与（制限付株式） |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Russell Lesley |
Director |
RSU 付与（制限付株式） |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Peterson Kristine |
Director |
RSU 付与（制限付株式） |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Vance Terry |
Director |
RSU 付与（制限付株式） |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-03-13 |
Hata Yujiro S |
Director |
RSU 付与（制限付株式） |
15,700 |
$6.83 |
$107.23K |
15,700 |
| 2025-02-12 |
Luly Jay R. |
President and CEO |
情報に基づく買い |
45,000 |
$5.69 |
$256.05K |
846,638 |
| 2025-02-12 |
Mellett Paul J |
Chief Fin. & Admin Officer |
RSU 源泉徴収 |
3,326 |
$5.59 |
$18.59K |
95,884 |
| 2025-02-12 |
Luly Jay R. |
President and CEO |
RSU 源泉徴収 |
7,484 |
$5.59 |
$41.84K |
864,654 |
| 2025-02-12 |
Or Yat Sun |
Chief Scientific Officer |
RSU 源泉徴収 |
4,324 |
$5.59 |
$24.17K |
374,535 |
| 2025-02-12 |
Kieffer Tara Lynn |
Chief Product Strategy Officer |
RSU 源泉徴収 |
3,326 |
$5.59 |
$18.59K |
33,479 |
| 2025-02-12 |
Luu Brendan |
Chief Business Officer |
RSU 源泉徴収 |
3,326 |
$5.59 |
$18.59K |
40,221 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
